Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06033950

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

Led by Colorado Prevention Center · Updated on 2025-03-11

2600

Participants Needed

8

Research Sites

188 weeks

Total Duration

On this page

Sponsors

C

Colorado Prevention Center

Lead Sponsor

S

St. Luke's Hospital, Kansas City, Missouri

Collaborating Sponsor

AI-Summary

What this Trial Is About

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

CONDITIONS

Official Title

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide electronic or written informed consent, either personally or through a legally authorized representative
  • Age 18 years or older or legal age of majority in participant's country
  • Symptomatic heart failure with reduced ejection fraction per protocol criteria
  • Not receiving steroidal mineralocorticoid receptor antagonists due to intolerance, contraindication, or ineligibility
  • Negative pregnancy test and agreement to use contraception during trial (female participants only)
Not Eligible

You will not qualify if you...

  • Treatment with non-steroidal mineralocorticoid receptor antagonists
  • History of severe hyperkalemia related to mineralocorticoid receptor antagonist use
  • Estimated glomerular filtration rate below 25 mL/min/1.73m² or potassium above 5.0 mmol/L
  • Acute myocardial infarction, coronary revascularization, valve replacement/repair, or cardiac resynchronization therapy device implantation within 30 days or planned
  • Prior or planned heart transplant
  • Severe uncorrected primary cardiac valvular disease causing heart failure
  • Symptomatic bradycardia or second/third-degree heart block without a pacemaker
  • Cardiomyopathy caused by acute inflammatory heart disease, infiltrative or accumulation diseases, muscular dystrophies, reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction
  • Alternative probable cause of heart failure
  • Use of potent cytochrome P450 3A4 inhibitors or moderate/strong CYP3A4 inducers
  • Known hypersensitivity to the investigational drug or its ingredients
  • Any condition or therapy making participation unsuitable
  • Participation in another interventional clinical trial with investigational agents within 30 days prior to randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

FIN-10004 Fairhope, AL Investigational Site

Fairhope, Alabama, United States, 36532

Actively Recruiting

2

FIN-10075 San Diego, CA Investigational Site

San Diego, California, United States, 92243

Actively Recruiting

3

FIN-10002 Kansas City, MO Investigational Site

Kansas City, Missouri, United States, 64111

Actively Recruiting

4

FIN-10015 Austin, TX Investigational Site

Austin, Texas, United States, 78705

Actively Recruiting

5

FIN-21003 Goiania, Goias Investigational Site

Goiânia, Goiás, Brazil, 74453-200

Actively Recruiting

6

FIN-21049 Sao Paulo, Investigational Site

Sao Paulp, Sap Paulo, Brazil, 05652-900

Actively Recruiting

7

FIN-21004 Braganca Paulista, Investigational Site

Bragança Paulista, São Paulo, Brazil, 12916542

Actively Recruiting

8

FIN-11012 Surrey, BC Investigational Site

Surrey, British Columbia, Canada, V3V OC6

Actively Recruiting

Loading map...

Research Team

M

Marc Bonaca

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists | DecenTrialz